Back to Journals » Cancer Management and Research » Volume 11

Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo

Authors Ubezio P

Received 15 May 2019

Accepted for publication 14 August 2019

Published 19 September 2019 Volume 2019:11 Pages 8529—8538

DOI https://doi.org/10.2147/CMAR.S215729

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Paolo Ubezio

Biophysics Unit, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

Correspondence: Paolo Ubezio
Istituto di Ricerche Farmacologiche Mario Negri – IRCCS, Via Mario Negri 2, Milan 20156, Italy
Tel +39-02-3901 4438
Fax +39-02-354 6277
Email paolo.ubezio@marionegri.it

Abstract: Assessing the efficacy of anticancer agents in animal models remains a necessary step in the development of new treatment options and plays an important role in their optimization and comparison. Often, however, interpretation of the results is flawed by excessive trust in scores traditionally handed down, but whose origin and limitations have been lost. Here I examine the theories and assumptions underlying the most common rating scales, suggesting improvements to the old scores and proposing the adoption of multi-parameter analysis and interpretation of the results, considering different time-windows. I examined case examples of different scenarios of antiproliferative effects induced by treatment, demonstrating that common scores fail to distinguish between completely different responses to treatment or, in other circumstances, indicate a different outcome when the response is the same. I found that a combination of parameters, including the percent tumor growth between the start and end of treatment, the relative tumor burden at nadir and the absolute growth delay, may distinguish among the different cases and support a correct interpretation of the antitumor response. All these parameters can be derived from individual tumor growth curves in a simple way, without any change to common experimental procedures.

Keywords: tumor growth curves, T/C ratio, treatment evaluation, anticancer activity, preclinical testing, cell proliferation, cell killing, tumor growth delay


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]